A Randomized, Double Blind, Placebo-Controlled, Multicenter Trial of Allisartan Isoproxil for treatment of Essential Hypertensive Population at Low-Medium Risk.
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Allisartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 21 May 2012 Actual end date changed from Nov 2009 to Jan 2010as reported by Chinese Clinical Trial Register record.
- 09 Jan 2012 Actual initiation date changed from 1Jul 2009 to 1 Apr 2009 as reported by Chinese Clinical Trial Register.
- 09 Jun 2010 New trial record